Drugs / VSF-173
re-read 3 minutes ago

VSF-173

Developed for
hypersomnia
Investigated by
Vanda Pharmaceuticals

Trials 1

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00467441 — hypersomnia Vanda Pharmaceuticals Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as VSF-173 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00467441 ↗